Management of Transthyretin Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Guides & Guidelines

Management of Transthyretin Amyloidosis

key information

source: Swiss Medical Weekly

year: 2021

authors: Adalgisa Condoluci, Marie Théaudin, Rahel Schwotzer, et al.

summary/abstract:

These guidelines were written after an extensive literature search using MedLine publications from January 1980 to April 2021, under the terms “ATTR” AND “transthyretin” AND “amyloidosis”. Only full articles in English were considered. Following the literature search and review, the steering committee developed a summary of relevant statements that were evaluated by all the participants. Consensus was established using online, single point-per-point voting, through a nominal group technique. Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical heterogeneity of ATTR amyloidosis and the variable presentation of symptoms at early disease stages, historically meant treatment delays. Diagnostic tools and therapy options of ATTR amyloidosis have markedly improved in recent years.

 

organization: Oncology Institute of Southern Switzerland, Switzerland; University Hospital and University of Lausanne, Switzerland; University Hospital of Zurich, Switzerland; ETHZ, Switzerland; Cardiocentro Ticino, Switzerland; University of Bern, Switzerland; Università della Svizzera Italiana, Switzerland; Swiss Institute of Bioinformatics, Switzerland; University Hospital and University of Basel, Switzerland; Cantonal Hospital Graubünden, Switzerland; Cantonal Hospital Aarau, Switzerland; University Hospital and University of Geneva, Switzerland; Luzerner Kantonsspital, Switzerland; Università della Svizzera Italiana, Switzerland;

DOI: 10.4414/smw.2021.w30053

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close